Celtaxsys Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Celtaxsys Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10550
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celtaxsys Inc (Celtaxsys) is a clinical-stage pharmaceutical development company that develops novel foundational therapies to treat inflammation in rare, orphan designated diseases. Oral once daily acebilustat, the company’s flagship drug candidate under phase 2 clinical trial, is intended to preserve lung function in cystic fibrosis. The company has expertise to discover, develop and commercialize new therapies across a wide variety of disease states. The company has its operations in the US and Australia. Celtaxsys is headquartered in Atlanta, Georgia, the US.

Celtaxsys Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Celtaxsys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Celtaxsys Acquires CTX-4430 From Estrellita Pharma 10
Venture Financing 11
Celtaxsys Raises Funds through Series E Financing 11
Celtaxsys Raises USD40 Million in Series D Financing 13
Celtaxsys Inc – Key Competitors 15
Celtaxsys Inc – Key Employees 16
Celtaxsys Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Corporate Communications 18
Jan 09, 2017: Celtaxsys Welcomes New Board Member Abel De La Rosa 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Celtaxsys Inc, Pharmaceuticals & Healthcare, Key Facts 2
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Celtaxsys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Celtaxsys Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Celtaxsys Acquires CTX-4430 From Estrellita Pharma 10
Celtaxsys Raises Funds through Series E Financing 11
Celtaxsys Raises USD40 Million in Series D Financing 13
Celtaxsys Inc, Key Competitors 15
Celtaxsys Inc, Key Employees 16
Celtaxsys Inc, Subsidiaries 17

List of Figures
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Celtaxsys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Celtaxsys Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Barton Malow Company:戦略・SWOT・企業財務分析
    Barton Malow Company - Strategy, SWOT and Corporate Finance Report Summary Barton Malow Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Meijer Inc:企業の戦略・SWOT・財務情報
    Meijer Inc - Strategy, SWOT and Corporate Finance Report Summary Meijer Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Canadian Imperial Bank of Commerce:企業のM&A・事業提携・投資動向
    Canadian Imperial Bank of Commerce - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Canadian Imperial Bank of Commerce Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • American Bio Medica Corp (ABMC):企業の財務・戦略的SWOT分析
    Summary American Bio Medica Corp (ABMC) is a biotechnology company that develops, manufactures and markets immunoassay test kits. The company’s products include Rapid TOX, a point of collection testing product that detects 1-10 drugs of abuse in a urine specimen; Rapid One, a test cassette which is …
  • Osprey Medical Inc (OSP):医療機器:M&Aディール及び事業提携情報
    Summary Osprey Medical Inc (Osprey Medical) is a medical device company that designs, develops, and manufacturers proprietary devices and monitoring systems. The company offers contrast removal system, which is designed to provide cardiologists with an advanced level of CIN protection in high risk p …
  • Source Plc:企業の戦略・SWOT・財務情報
    Source Plc - Strategy, SWOT and Corporate Finance Report Summary Source Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Australian Pharmaceutical Industries Ltd (API):企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • University of Louisville-製薬・医療分野:企業M&A・提携分析
    Summary University of Louisville (UofL) is an educational university that offers undergraduate, graduate, post-baccalaureate pre-med program, dentistry, law and online programs. The university offers courses such as accountancy, aerospace studies, art education, bioengineering, business administrati …
  • Mamee-Double Decker (M) Berhad:企業の戦略的SWOT分析
    Mamee-Double Decker (M) Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Wintrust Financial Corporation:企業のM&A・事業提携・投資動向
    Wintrust Financial Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wintrust Financial Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Arden Partners Plc (ARDN):企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Its distribution services include providing unique trading though …
  • Cardiovascular Systems Inc (CSII):製品パイプライン分析
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for treating peripheral and coronary vascular disease. The company offers products such as peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accessorie …
  • ams AG (AMS):企業の財務・戦略的SWOT分析
    Summary ams AG (ams) involves in manufacturing and marketing of semiconductor products. The offers various company's which include ultra small ANC speaker driver, environmental sensors, spectral sensing, CMOS imaging sensors, DC-DC boost converters and CT and digital X-ray . It offers power manageme …
  • TenCate Advanced Armour:企業の戦略・SWOT・財務情報
    TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report Summary TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Amcor Limited:企業の戦略・SWOT・財務情報
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Australia and New Zealand Banking Group Ltd:企業のM&A・事業提携・投資動向
    Australia and New Zealand Banking Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Australia and New Zealand Banking Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Tethys Oil AB (TETY):企業の財務・戦略的SWOT分析
    Summary Tethys Oil AB (Tethys Oil) is an upstream oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company holds onshore exploration licences in Lithuania and France. Tethys Oil holds Gargzdai license, Rietavas license and Raseiniai license …
  • Gunvor Group Limited:石油・ガス:M&Aディール及び事業提携情報
    Summary Gunvor Group Limited (Gunvor) is a vertically integrated energy trading company. It is one of the global traders of physical crude oil; refined products and energy; and metals and bulk materials. The company provides integrated trading products and logistics service to connect upstream suppl …
  • Viralytics Ltd (VLA)-製薬・医療分野:企業M&A・提携分析
    Summary Viralytics Ltd (Viralytics), formerly Psiron Ltd is a provider of development and commercialisation of oncolytic immunotherapies. The company develops oncolytic immunotherapies for the treatment of different types of cancers. It offers cavataktm, a proprietary formulation for the common cold …
  • DiaSorin SpA (DIA):企業の財務・戦略的SWOT分析
    DiaSorin SpA (DIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆